Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial

Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial

Abstract Background Acute respiratory distress syndrome (ARDS) is the devastating complication of the new COVID-19 pandemic, directly correlated with releasing large amounts of inflammatory cytokines. Due to their immunoregulatory features, mesenchymal stromal cells (MSCs) provide a promising approa...

Full description

Bibliographic Details
Main Authors: Najmeh Kaffash Farkhad, Alireza Sedaghat, Hamidreza Reihani, Amir Adhami Moghadam, Ahmad Bagheri Moghadam, Nayereh Khadem Ghaebi, Mohammad Ali Khodadoust, Rashin Ganjali, Amir Reza Tafreshian, Jalil Tavakol-Afshari
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Stem Cell Research & Therapy
Subjects:
Mesenchymal stromal cells
Safety
Clinical trial
Acute respiratory distress syndrome
Online Access:https://doi.org/10.1186/s13287-022-02920-1

Internet

https://doi.org/10.1186/s13287-022-02920-1

Similar Items